Previous 10 | Next 10 |
Announcing preclinical data for its dual Aβ/tau vaccine targeted at Alzheimer’s disease, clinical-stage biotech Prothena Corporation (NASDAQ:PRTA) said on Wednesday that the company plans for an Investigational New Drug (IND) application for the candidate in 2023. In Addition, P...
Oral presentation on preclinical data demonstrates Prothena’s dual Aβ/tau vaccine, for the potential treatment and prevention of Alzheimer’s, generated anti-Aβ and anti-tau antibodies to enable phagocytosis of Aβ and to neutralize tau Preclinical dat...
KAR Auction Services (NYSE:KAR) +65% on offloading ADESA U.S. Physical Auction business to Carvana for $2.2B. Farfetch (NYSE:FTCH) +30% on Q4 results. Universal Security Instruments (NYSE:UUU) +28% and Infinite Reality, Inc jointly announce merger agreement. Cyren (NA...
Prothena Corporation plc (PRTA) Q4 2021 Earnings Conference Call February 17, 2022 04:30 PM ET Company Participants Jennifer Zibuda - Director-Investor Relations & Communications Gene Kinney - President & Chief Executive Officer Tran Nguyen - Chief Financial Officer & Chief Strate...
Prothena press release (NASDAQ:PRTA): Q4 GAAP EPS of -$0.71. Revenue of $1.17M (+225.0% Y/Y). FY 2022 Guidance: The company expects the full year 2022 net cash used in operating and investing activities to be $120 to $132 million, which includes an expected $40 million clinical milestone paym...
Net cash used in operating and investing activities was $22.8 million in the fourth quarter and net cash provided by operating and investing activities was $92.0 million for the full year 2021; quarter-end cash and restricted cash position was $580.4 million ...
AEE, AEL, AJRD, AL, AMN, APPN, ATR, AUY, BJRI, CGNX, CHRS, CHUY, CMBM, CNNE, CWST, CYBE, DBX, DLR, ED, EXEL, GDEN, GLOB, GMED, HASI, IVR, JAKK, KEYS, KNSL, LASR, LBTYA, LGND, LNT, LTC, LTHM, OTCPK:LUNMF, MATX, MSA, NR, NYMT, OPK, PK, PRTA, QDEL, RDFN, RLGY, ROKU, RUN, SAND, SHAK, SJW, SKT, SW...
DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its fourth quarter and ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips With its latest variant (Omicron) spreading, it seems Covid-19 will continue to play a major role in world events in 2022, just like it did in 2020, and in 2021. With this, pandemic-related drug stocks will likely remain ho...
The electric vehicle sector is mostly higher after riding out some negative news yesterday with Lucid Group (LCID -3.3%) disclosing a SEC subpoena and Tesla (TSLA +3.0%) reportedly being probed over solar panel fire risk. Helping to boost sentiment, several Wall Street economists are mak...
News, Short Squeeze, Breakout and More Instantly...
Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
Prothena Corporation plc Website:
2024-07-03 23:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-02 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Prothena to receive $80 million from Bristol Myers Squibb for exclusive global license to PRX019, a potential treatment of neurodegenerative diseases with an undisclosed target Prothena will initiate a Phase 1 clinical trial for PRX019 in 2024 Prothena Corporation plc (NASDAQ:PRTA),...